Literature DB >> 36040519

Single-cell and spatial transcriptome analyses revealed cell heterogeneity and immune environment alternations in metastatic axillary lymph nodes in breast cancer.

Xiaofan Mao1,2, Dan Zhou3, Kairong Lin1,2, Beiying Zhang1,2, Juntao Gao4, Fei Ling5, Lewei Zhu3, Sifei Yu1,2, Peixian Chen3, Chuling Zhang1,2, Chunguo Zhang1,2, Guolin Ye3, Simon Fong6, Guoqiang Chen7, Wei Luo8,9.   

Abstract

BACKGROUND: Tumor heterogeneity plays essential roles in developing cancer therapies, including therapies for breast cancer (BC). In addition, it is also very important to understand the relationships between tumor microenvironments and the systematic immune environment.
METHODS: Here, we performed single-cell, VDJ sequencing and spatial transcriptome analyses on tumor and adjacent normal tissue as well as axillar lymph nodes (LNs) and peripheral blood mononuclear cells (PBMCs) from 8 BC patients.
RESULTS: We found that myeloid cells exhibited environment-dependent plasticity, where a group of macrophages with both M1 and M2 signatures possessed high tumor specificity spatially and was associated with worse patient survival. Cytotoxic T cells in tumor sites evolved in a separate path from those in the circulatory system. T cell receptor (TCR) repertoires in metastatic LNs showed significant higher consistency with TCRs in tumor than those in nonmetastatic LNs and PBMCs, suggesting the existence of common neo-antigens across metastatic LNs and primary tumor cites. In addition, the immune environment in metastatic LNs had transformed into a tumor-like status, where pro-inflammatory macrophages and exhausted T cells were upregulated, accompanied by a decrease in B cells and neutrophils. Finally, cell interactions showed that cancer-associated fibroblasts (CAFs) contributed most to shaping the immune-suppressive microenvironment, while CD8+ cells were the most signal-responsive cells.
CONCLUSIONS: This study revealed the cell structures of both micro- and macroenvironments, revealed how different cells diverged in related contexts as well as their prognostic capacities, and displayed a landscape of cell interactions with spatial information.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Breast cancer; Circulating immune system; Immune and stromal cell heterogeneity; Metastatic lymph nodes; Single-cell and spatial sequencing

Year:  2022        PMID: 36040519     DOI: 10.1007/s00262-022-03278-2

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.630


  72 in total

1.  Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.

Authors:  Brian D Lehmann; Joshua A Bauer; Xi Chen; Melinda E Sanders; A Bapsi Chakravarthy; Yu Shyr; Jennifer A Pietenpol
Journal:  J Clin Invest       Date:  2011-07       Impact factor: 14.808

2.  Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis.

Authors:  Peter Savas; Balaji Virassamy; Chengzhong Ye; Agus Salim; Christopher P Mintoff; Franco Caramia; Roberto Salgado; David J Byrne; Zhi L Teo; Sathana Dushyanthen; Ann Byrne; Lironne Wein; Stephen J Luen; Catherine Poliness; Sophie S Nightingale; Anita S Skandarajah; David E Gyorki; Chantel M Thornton; Paul A Beavis; Stephen B Fox; Phillip K Darcy; Terence P Speed; Laura K Mackay; Paul J Neeson; Sherene Loi
Journal:  Nat Med       Date:  2018-06-25       Impact factor: 53.440

3.  Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.

Authors:  Carsten Denkert; Gunter von Minckwitz; Silvia Darb-Esfahani; Bianca Lederer; Barbara I Heppner; Karsten E Weber; Jan Budczies; Jens Huober; Frederick Klauschen; Jenny Furlanetto; Wolfgang D Schmitt; Jens-Uwe Blohmer; Thomas Karn; Berit M Pfitzner; Sherko Kümmel; Knut Engels; Andreas Schneeweiss; Arndt Hartmann; Aurelia Noske; Peter A Fasching; Christian Jackisch; Marion van Mackelenbergh; Peter Sinn; Christian Schem; Claus Hanusch; Michael Untch; Sibylle Loibl
Journal:  Lancet Oncol       Date:  2017-12-07       Impact factor: 41.316

4.  Tumor-infiltrating lymphocytes (TILs) in ER+/HER2- breast cancer.

Authors:  C Criscitiello; A Vingiani; P Maisonneuve; G Viale; G Viale; G Curigliano
Journal:  Breast Cancer Res Treat       Date:  2020-07-03       Impact factor: 4.872

Review 5.  Mammary stem cells and the differentiation hierarchy: current status and perspectives.

Authors:  Jane E Visvader; John Stingl
Journal:  Genes Dev       Date:  2014-06-01       Impact factor: 11.361

6.  Cell state plasticity, stem cells, EMT, and the generation of intra-tumoral heterogeneity.

Authors:  Geoffrey M Wahl; Benjamin T Spike
Journal:  NPJ Breast Cancer       Date:  2017-04-19

7.  Ror2-mediated alternative Wnt signaling regulates cell fate and adhesion during mammary tumor progression.

Authors:  K Roarty; A D Pfefferle; C J Creighton; C M Perou; J M Rosen
Journal:  Oncogene       Date:  2017-06-26       Impact factor: 9.867

8.  An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer.

Authors:  Andrew E Teschendorff; Ahmad Miremadi; Sarah E Pinder; Ian O Ellis; Carlos Caldas
Journal:  Genome Biol       Date:  2007       Impact factor: 13.583

9.  HER2 expression identifies dynamic functional states within circulating breast cancer cells.

Authors:  Nicole Vincent Jordan; Aditya Bardia; Ben S Wittner; Cyril Benes; Matteo Ligorio; Yu Zheng; Min Yu; Tilak K Sundaresan; Joseph A Licausi; Rushil Desai; Ryan M O'Keefe; Richard Y Ebright; Myriam Boukhali; Srinjoy Sil; Maristela L Onozato; Anthony J Iafrate; Ravi Kapur; Dennis Sgroi; David T Ting; Mehmet Toner; Sridhar Ramaswamy; Wilhelm Haas; Shyamala Maheswaran; Daniel A Haber
Journal:  Nature       Date:  2016-08-24       Impact factor: 49.962

Review 10.  Mechanisms of immune evasion in breast cancer.

Authors:  Joshua P Bates; Roshanak Derakhshandeh; Laundette Jones; Tonya J Webb
Journal:  BMC Cancer       Date:  2018-05-11       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.